LB Pharmaceuticals Inc Common Stock (LBRX)

About LB Pharmaceuticals Inc Common Stock

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 110 institutions reported holding LBRX, with 29.8 million shares worth $965.9 million in aggregate. The largest reported holder was Deep Track Capital, with 3.4 million shares worth $108.8 million. Of the 5 largest holders listed below, 2 added shares and 3 held their positions unchanged during the quarter.

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions